EPHA4 and psychiatric disorder: In the context of animal models of neurodegenerative and psychiatric diseases, some studies have suggested that RHY acts on the central nervous system by preventing the activation (via phosphorylation) of the ephrin receptor EPHA4 as well as by preventing the activation of EPHA4 downstream pathways (e.g. CDK5 phosphorylation) [4, 5].